Latest Neurovascular Devices Interventional Neurology Market Research Report Cover Covid-19 Impact:

The Neurovascular Devices Interventional Neurology report provides an independent information about the Neurovascular Devices Interventional Neurology industry supported by extensive research on factors such as industry segments size & trends, inhibitors, dynamics, drivers, opportunities & challenges, environment & policy, cost overview, porters five force analysis, and key companies

Download Premium Sample Copy Of This Report:Download FREE Sample PDF!

In this report, our team offers a thorough investigation of Neurovascular Devices Interventional Neurology Market, SWOT examination of the most prominent players right now. Alongside an industrial chain, market measurements regarding revenue, sales, value, capacity, regional market examination, section insightful information, and market forecast are offered in the full investigation, and so forth.

Scope of Neurovascular Devices Interventional Neurology Market: Products in the Neurovascular Devices Interventional Neurology classification furnish clients with assets to get ready for tests, tests, and evaluations.

Major Company Profiles Covered in This Report

Stryker Corporation , Medtronic PLC , Johnson & Johnson , Terumo Corporation , Penumbra, Inc. , Boston Scientific Corporation , Microport Scientific Corporation , Merit Medical Systems, Inc. , W.L. Gore & Associates, Inc. , Abbott Laboratories

Have Any Query Or Specific Requirement?Ask Our Industry Experts!

Neurovascular Devices Interventional Neurology Market Report Covers the Following Segments:

Segmentation by Type:Aneurysm Coiling & Embolization DevicesEmbolic CoilsBare Detachable CoilsCoated Detachable CoilsFlow Diversion DevicesLiquid Embolic AgentsCerebral Balloon Angioplasty and Stenting SystemsCarotid Artery StentsEmbolic Protection SystemsDistal Filter DevicesBalloon Occlusion DevicesSupport DevicesMicrocathetersMicroguidewiresNeurothrombectomy DevicesClot Retrieval DevicesSuction and Aspiration DevicesSnaresSegmentation by Application:Ischemic StrokesCerebral AneurysmsArteriovenous Malformation and FistulasOther Disease pathology

Market Size Segmentation by Region & Countries (Customizable):

North America

Europe

Asia-Pacific

South America

Center East and Africa

United States, Canada and Mexico

Germany, France, UK, Russia and Italy

China, Japan, Korea, India and Southeast Asia

Brazil, Argentina, Colombia

Saudi Arabia, UAE, Egypt, Nigeria and South Africa

Table of Content:

Market Overview:The report begins with this section where product overview and highlights of product and application segments of the global Neurovascular Devices Interventional Neurology Market are provided. Highlights of the segmentation study include price, revenue, sales, sales growth rate, and market share by product.

Competition by Company:Here, the competition in the Worldwide Neurovascular Devices Interventional Neurology Market is analyzed, By price, revenue, sales, and market share by company, market rate, competitive situations Landscape, and latest trends, merger, expansion, acquisition, and market shares of top companies.

Company Profiles and Sales Data:As the name suggests, this section gives the sales data of key players of the global Neurovascular Devices Interventional Neurology Market as well as some useful information on their business. It talks about the gross margin, price, revenue, products, and their specifications, type, applications, competitors, manufacturing base, and the main business of key players operating in the global Neurovascular Devices Interventional Neurology Market.

Market Status and Outlook by Region:In this section, the report discusses about gross margin, sales, revenue, production, market share, CAGR, and market size by region. Here, the global Neurovascular Devices Interventional Neurology Market is deeply analyzed on the basis of regions and countries such as North America, Europe, China, India, Japan, and the MEA.

Application or End User:This section of the research study shows how different end-user/application segments contribute to the global Neurovascular Devices Interventional Neurology Market.

Market Forecast:Here, the report offers a complete forecast of the global Neurovascular Devices Interventional Neurology Market by product, application, and region. It also offers global sales and revenue forecast for all years of the forecast period.

Research Findings and Conclusion:This is one of the last sections of the report where the findings of the analysts and the conclusion of the research study are provided.

For detailed information https://brandessenceresearch.biz/Medical-Devices-and-Consumables/Neurovascular-Devices-Interventional-Neurology-Market-Register-Strong-Growth-to-2025/Summary

About Us:

We publish market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students.

Top Trending Reports:

http://www.marketwatch.com/press-release/new-zealand-milking-systems-market-share-industry-size-opportunities-analysis-growth-factors-and-forecast-2025-2020-11-17

https://www.marketwatch.com/press-release/fmcg-market-2020-size-share-global-industry-growth-business-statistics-top-leaders-competitive-landscape-forecast-to-2025-2020-11-12?tesla=y

https://www.marketwatch.com/press-release/cellulose-ester-market-size-global-industry-analysis-and-opportunity-assessment-2020-2025-2020-11-13?tesla=y

https://www.marketwatch.com/press-release/telemedicine-market-size-to-surpass-usd-14832-billion-by-2025-analysis-types-trends-share-industry-insights-trends-and-forecast-upto-2025-2020-08-12?tesla=y

https://www.marketwatch.com/press-release/over-2084-cagr-viral-vector-manufacturing-market-will-bypass-124-billion-by-2025-2020-11-12?tesla=y

Excerpt from:
What is Trending in Neurovascular Devices Interventional Neurology Market? What are the Strategies to Boost Business in Near Years? - The Daily...

Latest research with COVID-19 impact analysis of Global Neurology Devices Industry 2025 Situations, Growth, Prospects, & Sales Market is analyzed. The deep-dive analysis of Neurology Devices market development factors, risks & market maturity analysis is conducted. The research study is segmented based on top product types, applications, companies, & end-users. The Neurology Devices industry share & size analysis is conducted. The forecast strategies, Neurology Devices business plans, changing dynamics & policies are studied comprehensively. The crucial opportunities to focus on, market driving forces & statistics are evaluated.

The research report on Neurology Devices market offers a complete assessment of this business landscape while highlighting the production as well as the consumption aspects. Factors including growth drivers, limitations, and opportunities impacting the market dynamics are also specified in the document. A detailed five Porters analysis of each company operating in this industry is conducted to conclude emerging prospects.

The study specifies the major business strategies which offer a robust profit potential. However, the advent of COVID-19 outbreak may have major modifications in the expansion of the overall market. Thus, the report assesses and provides detailed assessment of the impact of COVID-19 pandemic on the market remuneration.

Request Sample Copy of this Report @ https://www.express-journal.com/request-sample/230462

Major parameters specified in the table of contents:

Additional takeaways from the Neurology Devices market report:

Neurology Devices research provides answers to the following key questions:

Request Customization on This Report @ https://www.express-journal.com/request-for-customization/230462

Link:
Neurology Devices Market Revenue, Growth Rate, Customer Needs, Trend, Manufacturers and Forecast to 2025 - Express Journal

Meet the Doctors of Memorial Hermann The Woodlands Medical Center who share information and experience on Deep Brain Stimulation, a surgical treatment option for patients suffering from Parkinsons disease and essential tremors.

Watch the video below with the Hello Woodlands interview with Dr. Allison Boyle and Dr. Saman Javedan:

Video produced by Rod Prado and Jennifer Bruse of Hello Woodlands

Dr. Allison Boyle is a board-certified neurologist specializing in neurology and movement disorders. Dr. Boyle is certified in botulinum toxin injections for dystonia, muscle spasm, sialorrhea or tremor; intrathecal baclofen pump therapy for the control of significant or severe spastic or dystonic tone; deep brain stimulation therapies for the control of tremor, signs and symptoms of Parkinsons disease and focal, segmental or generalized dystonia; and lumbar punctures.

Dr. Saman Javedan is a board-certified neurosurgeon and is board certified by the American Board of Neurological Surgery (ABNS). His areas of expertise include complex cranial tumors, complex spinal tumors, spinal reconstruction, spinal fusions, minimally invasive spine surgery, movement disorders, deep brain stimulation (DBS) and stereotactic radiosurgery (SRS).

Memorial Hermann-Texas Medical Center was the first hospital in Texas to implant the Food and Drug Administration (FDA) approved Percept PC Deep Brain Stimulation system by Medtronic in patients with neurologic disorders. With the investment of new technology and experienced doctors, the procedure is now available at Memorial Hermann The Woodlands Medical Center. The first-of-its-kind neurostimulator uses BrainSense Technology and has the ability to capture and record the users brain signals while delivering therapy to patients with neurologic disorders associated with such conditions as Parkinsons disease, essential tremor, dystonia, epilepsy or obsessive-compulsive disorder.

Patients undergo the deep brain stimulation system implantation in two phases over two hospital visits. During the first visit, the patient undergoes surgery to have electrodes implanted in their brain. On the patients second visit, connecting wires and neurostimulator is implanted.

Deep brain stimulation is a surgical treatment option for patients suffering from Parkinsons disease and other movement disorders. Through a small pacemaker-like device, the brain is sent mild electrical signals to a targeted area in the brain related to the symptoms of a neurological disorder. The signals help reorganize the brains electrical impulses and results in improved symptoms for many neurological conditions.

For more information on deep brain stimulation treatment at Memorial Hermann The Woodlands Medical Center visit http://neuro.memorialhermann.org/conditions-treatments/deep-brain-stimulation/.

Advertisement

Read the original here:
Meet the Doctor: Deep Brain Stimulation at Memorial Hermann The Woodlands - hellowoodlands.com

In patients hospitalized with coronavirus disease 2019 (COVID-19), stroke was associated with those who were older and presented with stroke risk factors. They were found to have a slightly higher frequency of stroke compared with the estimation for the general population, according to study results published in the Journal of Stroke and Cerebrovascular Diseases.

Study researchers sought to investigate the frequency and clinical characteristics of patients with both COVID-19 and stroke. This analysis was a systematic review of observational studies, case series, and case reports that disclosed the incidence of ischemic or hemorrhagic stroke in patients with COVID-19. In total, 10 retrospective cohort studies, 10 case reports, and 6 case series were included in the final meta-analysis. A pooled cohort of 183 patients with both COVID-19 and stroke were assessed.

Among the 6368 hospitalized patients with COVID-19, the reported frequency of stroke was 1.1% (95% CI, 95% CI, 0.6-1.6; I2=62.9%). The mean age of the study cohort was 66.6 years (95% CI, 58.4-74.9; I2=95.2%), and over half of the patients were men (65.6%). Comorbidities included hypertension (69.4%), dyslipidemia (44.4%), diabetes (43.5%), acute coronary syndrome/coronary artery disease (26.9%), atrial fibrillation (23.1%), prior stroke/transient ischemic attack (10.4%), and malignancy (14.8%).

In patients who had data describing their stroke type, approximately 96.6% had ischemic stroke. The mean number of days from the onset of COVID-19 symptoms to stroke was 8 days (95% CI, 4.1-11.9; I2=93.1%; I2=93.1%; P <.001). The mean D-dimer was 3.3 g/mL (95%CI, 1.7-4.9; I2=86.3%), and the mean C-reactive protein level was 127.8 mg/L (95% CI, 100.9-154.6; I2=0%).

In 50.7% of patients, the etiology of stroke was cryptogenic (95% CI, 31.0-70.4; I2=64.1%). Among 100 patients, the case fatality rate was 44.2% (95% CI, 27.9-60.5; I2=66.7%).

Limitations of this study included the small sample size, potential publication bias in the included case reports and series, and the presence of considerable heterogeneity in the pooled patient population.

The study researchers concluded that additional studies could be helpful to decipher the pathophysiology and prognosis of stroke in COVID-19 to achieve the most effective care for this population to decrease mortality.

Reference

Yamakawa M, Kuno T, Mikami T, Takagi H, Gronseth G. Clinical characteristics of stroke with COVID-19: A systematic review and meta-analysis. J Stroke Cerebrovasc Dis. 2020;29(12):105288. doi:10.1016/j.jstrokecerebrovasdis.2020.105288

Originally posted here:
Stroke Incidence Slightly Higher in Hospitalized Patients With COVID-19 - Neurology Advisor

CRANBURY, N.J., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced additional positive interim results from its CLN6 Batten disease gene therapy program, AT-GTX-501. The results are featured in a virtual poster presentation at the Joint 16th International Child Neurology Congress and 49th Annual Child Neurology Society Meeting being held October 12-23, 2020. The presentation is also available in the Events and Presentations section of the Amicus Therapeutics corporate website at http://ir.amicusrx.com/events-and-presentations.

The Abigail Wexner Research Institute (AWRI) at Nationwide Childrens Hospital is conducting the ongoing Phase 1/2 clinical study of a single one-time intrathecal administration of AT-GTX-501 gene therapy for variant late-infantile neuronal ceroid lipofuscinosis 6 (vLINCL6) disease, also known as CLN6 Batten disease. With no approved treatments, CLN6 Batten disease is a fatal neurologic disease that rapidly robs children of their ability to walk, speak, think, and see.

Clinical Data Highlights:Interim safety data are available for 13 children with CLN6 Batten disease. Interim efficacy data are available for the first 12 children reaching the 12-month timepoint and for eight children up to 24 months, post-administration of the AAV-CLN6 gene therapy.

Jeff Castelli, Ph.D., Chief Development Officer ofAmicus Therapeutics, stated, We are pleased to share these positive interim clinical data for our intrathecal AAV gene therapy with the CLN6 community. The data continues to suggest that our gene therapy has the potential to be a treatment option for children living with CLN6 Batten disease, an ultra-rare, debilitating condition that leads to progressive declines in cognitive and motor function, and often results in death early in life.

Emily de los Reyes, M.D., Ph.D., Principal Investigator of the CLN6 clinical trial at AWRI at Nationwide Childrens andProfessor of Clinical Pediatrics and Neurology at The Ohio State University College of Medicine, stated, I remain pleased with the progress of this trial as well as our collection of natural history data to further inform the results for the AAV-CLN6 gene therapy. The interim results show that this investigational gene therapy has the potential to slow the neurological disease progression in children with CLN6 Batten disease.

Regulatory interactions for AT-GTX-501 are ongoing and the Company expects to provide feedback on the path forward in 2021.

Amicus has exclusive rights to the CLN6 gene therapy program developed at the Abigail Wexner Research Institute at Nationwide Childrens Hospital.

About AT-GTX-501AT-GTX-501 is a novel gene therapy in Phase 1/2 development for CLN6 Batten disease, a rare, fatal, inherited lysosomal disorder with no approved treatment that primarily affects the nervous system. AT-GTX-501 is dosed in a one-time intrathecal infusion to deliver a functional copy of the CLN6 gene to cells of the central nervous system. The therapy is designed to address the underlying enzyme deficiency that results in progressive cell damage and neurodevelopmental and physical decline. In the U.S., AT-GTX-501 was granted Rare Pediatric Disease and Orphan Drug designations by the United States Food and Drug Administration. In the EU, the Company holds PRIME and orphan medicinal product designations.

About Batten DiseaseBatten disease is the common name for a broad class of rare, fatal, inherited disorders of the nervous system also known as neuronal ceroid lipofuscinoses, or NCLs. In these disorders, a defect in a specific gene triggers a cascade of problems that interferes with a cells ability to recycle certain molecules. Each gene is called CLN (ceroid lipofuscinosis, neuronal) and given a different number designation as its subtype. There are 13 known forms of Batten disease often referred to as CLN1-8; 10-14. The various types of Batten disease have similar features and symptoms but vary in severity and age of onset.

Most forms of Batten disease/NCLs usually begin during childhood. The clinical course often involves progressive loss of independent adaptive skills such as mobility, feeding and communication. Patients may also experience vision loss, personality changes, behavioral problems, learning impairment and seizures. Patients typically experience progressive loss of motor function and eventually become wheelchair-bound, are then bedridden and die prematurely.

About Amicus Therapeutics Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases. For more information please visit the companys website at http://www.amicusrx.com, and follow on Twitter and LinkedIn.

Forward-Looking StatementsThis press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of our product candidates, the timing and reporting of results from preclinical studies and clinical trials and the prospects and timing of the potential regulatory approval of our product candidates. In particular, this press release relates to interim data from an ongoing Phase 1/2 study to investigate intrathecal administration of AAV-CLN6 gene therapy. The inclusion of forward-looking statements arising from this interim data, ongoing study and natural history preliminary data should not be regarded as a representation by us that any of our plans will be achieved. Any or all of the forward-looking statements in this press release may turn out to be wrong and can be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. For example, with respect to statements regarding the goals, progress, timing, and outcomes of discussions with regulatory authorities, and in particular the potential goals, progress, timing, and results of preclinical studies and clinical trials, actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in our business, including, without limitation: the potential that results of clinical or preclinical studies indicate that the product candidates are unsafe or ineffective; the potential that it may be difficult to enroll patients in our clinical trials; the potential that regulatory authorities, including the FDA, EMA, and PMDA, may not grant or may delay approval for our product candidates; the potential that preclinical and clinical studies could be delayed because we identify serious side effects or other safety issues; and the potential that we will need additional funding to complete all of our studies. Further, the results of earlier preclinical studies and/or clinical trials may not be predictive of future results. The interim data and Phase 1/2 study discussed herein is inherently preliminary and early in the study, derived from a limited patient set, and later trial results with this patient set or others may not be consistent with these preliminary results. In addition, all forward-looking statements are subject to other risks detailed in our Annual Report on Form 10-K for the year ended December 31, 2019 and Quarterly Report on Form 10-Q for the quarter ended June 30, 2020. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and we undertake no obligation to revise or update this news release to reflect events or circumstances after the date hereof.

CONTACTS:

Investors:Amicus TherapeuticsAndrew FaughnanDirector, Investor Relationsafaughnan@amicusrx.com(609) 662-3809

Media:Amicus TherapeuticsDiana MooreHead of Global Corporate Communicationsdmoore@amicusrx.com(609) 662-5079

FOLDG

Read this article:
Amicus Therapeutics Announces Additional Positive Interim Clinical Data for CLN6 Batten Disease Gene Therapy at 49th Annual Meeting of the Child...

STEAMBOAT SPRINGS Opera Steamboat has announced plans to host two virtual seminars this month discussing neurological health themes from the book The Man Who Mistook His Wife for a Hat. The book was published in 1985 by neurologist Oliver Sacks and was subsequently turned into an opera the following year by composer Michael Nyman.

The seminars will introduce the content of the book and help set the stage for Opera Steamboats 2021 performance of the opera.

These seminars came as an idea to address the health issues around rural Colorado that as an organization we see on a regular basis, said Andres Cladera, general and artistic director of Opera Steamboat. Specifically, we wanted to address the neurological illnesses and mental health issues that our community are experiencing, while having difficulty getting treatment and/or support for the caregivers and families.

Cladera pointed out that up until recently, Steamboat did not have a regular neurologist on staff and patients would have to travel to Denver on a regular basis to seek treatment.

We have a lot of patrons and community members in Steamboat who have gone through neurological illnesses themselves or have taken care of a family member who has Parkinsons disease or Alzheimers, Cladera said. We want to bring awareness to the topic so that people can think about it and discuss it. Its not always easy to find treatment or care in rural Colorado.

The Man Who Mistook His Wife for a Hat describes the case histories of several of Sacks patients with the title based on one case in particular of a patient whom he refers to as Dr. P, who suffers from visual agnosia, a neurological condition that leaves him unable to recognize faces and objects.

Speakersfor the two seminars will include Dr. Ron Krall, a retired neurologist who lives in Steamboat; Dr. Samantha K. Holden, who is the assistant professor of neurology and medical director of the Memory Disorders Clinic at UCHealth, and Barbara Bronner, a retired licensed medical social worker focusing on issues of aging and caregiver support groups for the Alzheimers Association. Cladera will be a fourth speaker, discussing minimalism in the opera and how it relates to neuro illness.

Using music as a way of coping and understanding the world is a main theme, Cladera explained. When people suffer from neurological disorders, music can help them communicate and cope with their lives.

Dr. Krall, who owns Off the Beaten Path bookstore with his wife, will discuss the book.

From a literary standpoint, this is a book that is a piece of remarkable writing and reporting that makes for a wonderful education, he said. It illustrates the potential value of art in the treatment of the disease, in particular music, as it enables persons who have experienced some loss of neuro function to engage in relatively normal activities. Additionally, it teaches the importance of empathy for persons who have experienced a loss of function and support for them in obtaining care.

Those who wish to participate in the seminars can register for the two free seminars on Opera Steamboats website at operasteamboat.org/the-man-who-mistook-his-wife-for-a-hat.

The first seminar will take place at 5:30 p.m. Monday and the second at 5:30 p.m. Monday, Oct. 19. Participants will be emailed a Zoom link once they have registered.

Sophie Dingle is a contributing writer for Steamboat Pilot & Today.

Go here to see the original:
Opera Steamboat virtual seminars to tackle neurological health with discussion of 1985 book-turned-opera - Steamboat Pilot and Today

By Stephanie Cajigal October 8, 2020

Two neurologists contennd that stroke disparities are only partially explained by differences in the prevalence of traditional stroke risk factors between Black and White patients. They discuss the framework for understanding the effects of racism on stroke risk and where the field needs to go from here.

Black Americans are twice as likely to have a stroke and 40 percent more likely to die from one as compared with White Americans, according to the Centers for Disease Control and Prevention. Although decades of research have highlighted racial stroke disparities, there is a dearth of evidence on why they exist.

Now two prominent stroke neurologists are calling on the field to investigate how racism may impact vascular health. In an opinion article published online on August 21st in JAMA Neurology, Bruce Ovbiagele, MD, FAAN, and Olajide A. Williams, MD, note that stroke disparities are only partially explained by differences in the prevalence of traditional stroke risk factors between Black and White patients.

Dr. Ovbiagele, professor of neurology at the University of California San Francisco Weill Institute for Neurosciences, and Dr. Williams, professor and chief of staff of the department of neurology at the Columbia University Vagelos College of Physicians and Surgeons, recently spoke with Neurology Today about a framework for understanding the effects of racism on stroke risk and where the field needs to go from here.

Dr. Ovbiagele: While stroke disparities have been well documented, we haven't fully resolved what all the explanations or solutions are. This is an issue that has been pervasive for five decades. As you saw from the article, we can only explain about half of what seems to be contributing to Black-White disparity in terms of stroke outcomes.

Dr. Williams: I think the nation is sensitized, the world is sensitized, given the events of George Floyd in addition to the devastating disparities that were illuminated by COVID-19. Bruce and I have been working within the world of health disparities for decades, but it's amazing just how few Americans understand the severity of these disparities and how they impact all of us. I think COVID really showed the interconnectedness of all of us in society, whether you are the cleaning person going into a patient's room, or whether you are the physician walking into it, or a nurse, or a nursing aide. If one of those people in that chain has COVID, everyone is at risk. It shows we have to take care of the least among us. We thought we should take advantage of this moment by expanding the knowledge of the academic community on this topic.

Dr. Williams: Institutionalized racism is the codification of discrimination and bias into the structures of societies. These structural biases are driven by individual-level biases. For example, if I put a group of biased individuals on the governance committee of a particular organization, those individuals will translate their bias into policies and procedures. And then there is internalized racism, which is the effect of chronic racism on an individual. Chronic discrimination, chronic dehumanization, chronic marginalization causes the individual on the receiving end to ask, what is my worth? Before you know it, that individual will start internalizing the worth that society has placed on him. Once you internalize racism, it can be self-destructive.

What happens across these different levels is the systematic denial of opportunities such as access to health care. There is also the denial of diversity within health care by discriminating against people of color seeking admission into the medical field. This was highlighted by the Flexner Report [on medical education in the United States and Canada, originally published in 2010].

So structurally, you're being denied access, denied opportunities, and denied the ability to improve diversity within medicine. Personally, you're experiencing daily discrimination. Bruce and I included the Everyday Discrimination Scale in our paper to highlight the daily injustices experienced by people of color as a result of personally mediated racism. That in itself can be quite traumatic; it can generate anxiety, it can generate chronic stress responses, which in turn can lead to higher levels of inflammation, hypertension, etc. Couple that with decreased access to get these things fixed; couple that with decreased motivation to get these things addressed because you don't value yourself. Now you're dealing with a perfect storm that may lead to strokes and earlier mortality among people of color.

Dr. Ovbiagele: What we do know is that on the surface, at least, there are clearly differences in the timeliness and appropriateness of care that is delivered to Black people either at risk for stroke or who have experienced stroke. Can you categorically say that is due to racism? It is very hard to say. But that is what we are trying to call people to look into. If we don't have clear evidence pointing in one direction, it would be hard to design interventions or solutions to address it.

Dr. Williams: The 2013 Institute of Medicine report, Unequal Treatment, reviewed examples of implicit biases in medicine and showed quite tangibly that due to implicit bias, Black individuals may not receive the same level of pain treatment as White individuals. They showed that Black individuals may not get appropriate referrals for cardiac catherization compared to White individuals. We need much more rigorous research into this area in order to best determine where our resources should be focused.

Dr. Ovbiagele: Specifically, for stroke, as noted in the American Stroke Association Racial-Ethnic Disparities in Stroke Care statement in 2011. Black individuals have longer waiting times in the emergency department and are less likely to receive tPA or carotid revascularization procedures than White individuals.

Dr. Williams: I think the vascular effects of racism need to be better studied. For example, we now know the effects of rumination on blood pressure. We know that among people who are exposed to a racist eventsuch as when police pull someone over, grab him/her out of their car, and handcuff that person because he/she is Blackblood pressure surges due to the acute stress response at that moment. But these events are not isolated experiences, and so the cycle repeats itself. Moreover, the events are also replayed in your mind in the form of recurrent nightmares, the post-traumatic stress disorder of that experience. So not only is the experience continuing to happen in the real world, you're also being assaulted by the memory of the experience over and over again. All this causes vascular effects and inflammatory responses.

Dr. Ovbiagele: We need more representation of people of color but especially African-Americans in trials... I think we need to incorporate measures of discrimination and racism into trials as well. I would like to see those as endpoints in trials. I think those are the things that could be done almost immediately, and it would be wonderful to get the NIH to encourage that. I think grooming more researchers of all stripes; it doesn't have to be just people of color, who are interested in health inequities, to consider studying the issue of racism, would also be very important. We need more training programs to help people develop their careers in stroke disparities research. We need all hands-on deck if we are actually going to successfully tackle this issue.

Dr. Williams: There aren't enough Black neurologists, certainly not enough Black stroke neurologists to do the volume of work required. Because this is a societal problem, it's critically important for us to mobilize not just people of color, but allies who feel passionate about this injustice to join hands and help with the research and solutions.

Dr. Ovbiagele: Advocacy with nongovernmental organizations, professional organizations like the American Academy of Neurology, the American Neurological Association, the American Stroke Association, as well as major funders like the NIH. And, also not to just make this an American issue...this is a call to motivate a global cohort of people to address potentially racism-contributing stroke disparities in their countries.

Dr. Williams: There have been many acts of racism in medicine against the Black community, such as [the Tuskegee Study of Untreated Syphilis in the Negro Male] that have really drowned the confidence that people of color have with the health care system. They need truth and reconciliation. They need to be told that it's not in their minds; it's not in their heads. This is real, and it happened, and it is still happening. There needs to be acknowledgment before there is that recovery.

Dr. Williams: It all begins with the individual. I would say, listen, learn, and become an ally.

Dr. Ovbiagele: Undergo implicit bias and cultural sensitivity awareness training. Look at your own practice and routinely examine whether there are racial differences in care and outcomes among the stroke patients you see and address them. Lend your voice to support studies and programs aiming to eliminate this prominent and long-standing health disparity in our country. In Forecasting the Future of Stroke in the United States (Stroke. 2013;44:2361-2375), it's been projected that racial/ethnic disparities in stroke will likely worsen with time, without new concerted efforts, so there is no time like the present to strongly address this issue.

Drs. Williams and Ovbiagele reported no relevant disclosures.

Read more:
More Research Is Needed to Understand How Racism... : Neurology Today - LWW Journals

The ability to create and respond to music is said to be one of the key evolutionary developments made by humankind. Humans found meaning in music long before finding meaning in words. This is the reason why understanding the human brains connection with music has been an area of interest for scientists for centuries now. Many studies have shown that getting musical training can hone many cognitive skills and functions.

A study published in 2009 in the Journal of Neuroscience indicated that just 15 months of musical training in early childhood can improve musically relevant motor and auditory skills thanks to training-induced structural changes in the brain. Another study in BJPsych International in 2017 shows that the way music stimulates the brain can be used as a non-invasive psychotherapeutic method to treat neurological disorders like autism spectrum disorder, Alzheimers disease and Parkinsons disease. This study also suggests that music therapy can aid children with epilepsy.

Music for attention and memory

A new study published in Frontiers in Neuroscience has found new evidence to support this beneficial link between music and the human brain. The Chile-based researchers behind this study have discovered that children who are trained in music, especially those who learn to play an instrument, not only have better memory and concentration levels but also the parts of their brain related to attention, focus control and auditory encoding are more activated. This brain activation enables them to be better readers, have higher resilience towards adversity, greater creativity and therefore have a better quality of life.

The study included 40 healthy, right-handed, Spanish-speaking children aged 10-13 years, all of whom had normal hearing and normal or correct-to-normal (meaning they wear glasses or contact lenses) vision. Twenty of these children were musically trained members of youth orchestras in Santiago, Chile, with at least two years of instrumental training. These participants practiced their instruments (ranging from flutes and clarinets to violins and cellos) at least two hours per week, had orchestra rehearsals at least once a week and had started their musical training around the age of nine years.

The other 20 participants of the study were recruited from Santiagos public schools and had no musical training beyond what was given in their school. Unlike the musically-trained group, these children were unable to read or write musical scores. The attention and working memory of all participants was tested by the researchers using something called a bimodal (auditory/visual) attention and working memory (WM) task. During these tasks, the participants were exposed to visual and auditory stimuli and their brain activity was measured using functional magnetic resonance imaging (fMRI).

The study found that there were two mechanisms that contributed to the marked improvements in attention and memory of the musically trained participants. First, these children had a higher activation level of the fronto-parietal control network of the brain which is linked to attention, focus and concentration mechanisms. Second, these kids also had higher activation of two other parts of the brain - left inferior frontal gyrus (IFG) and left supramarginal gyrus (SMG) - which are linked with the phonological loop. The phonological loop is the component of working memory that keeps auditory information active in the consciousness, thereby helping memory recall and problem-solving abilities.

The study found that while these parts of the brain were highly activated among musically-trained participants, the same did not occur with the other children. The researchers, therefore, recommend musical training for all children to improve cognitive abilities like attention and memory. Moreover, the researchers insist that such training would not only help children develop their minds better but also bring them joy by being able to learn the universal language of music.

For more information, read our article on Tips to improve brain power.

Health articles in Firstpost are written by myUpchar.com, Indias first and biggest resource for verified medical information. At myUpchar, researchers and journalists work with doctors to bring you information on all things health.

Continue reading here:
Musical training in childhood likely to improve memo.. aid treatment of neurological disorders, find studies - Firstpost

New research from the results of a 1000-person study suggests improving blood sugar control could improve brain health for individuals with type 2 diabetes.

An analysis of data from the Look AHEAD (Action for Health In Diabetes) study, results of the study indicate improvements in glycemic control, but not weight status were linked to better subsequent cognitive performance.

"It's important to properly control your blood sugar to avoid the bad brain effects of your diabetes," saidOwen Carmichael, PhD, professor and director of Biomedical Imaging at the Louisiana State University Pennington Biomedical Research Center, in a statement. Don't think you can simply let yourself get all the way to the obese range, lose some of the weight, and everything in the brain is fine. The brain might have already turned a corner that it can't turn back from."

With an interest in how disease management might impact the cognitive function of in patients with type 2 diabetes, Carmichael and a team of colleagues hoped to design a study to describe associations between physiological markers and cognitive performance in patients with diabetes in the Look AHEAD study. A randomized controlled trial assessing the efficacy of intensive lifestyle intervention, the study provided data related to more than 5000 diabetic patients aged 45-76 years old.

Patients included in the study randomized to the intensive lifestyle intervention were prescribed to a daily calorie goal of 1200-1800 and a physical activity goal of more than 175 minutes per week with the aim of inducing weight loss to average more than 7% at 1-year and to be maintained over time.

As part of the ancillary studies, patients from the Look AHEAD study were invited to take part in cognitive assessments and 3920 participants provided at least 1 cognitive assessment between years 8-13 of follow-up. These assessments provided investigators information related to short-term memory, planning, impulse control, attention, ability to switch between tasks, verbal learning, and overall memory. For the purpose of the current analysis, investigators only included patients who provided 2 or 3 cognitive assessments, which yielded a cohort of 1089 individuals.

Of the 1089 included in the study, the mean age was 58.36.7 years, 58.8% were female, and 84.5% of patients had a BMI of 30 kg/m2 or greater. Investigators pointed out all 1089 patients underwent at least 2 cognitive assessments and a cohort of 315 patients completed all 3 cognitive assessments.

Upon analysis, results of the study suggested greater improvements in blood sugar control were associated with increased cognitive scores. Specific associations included fasting blood glucose and Rey Auditory Verbal Learning Test (P=.0148), fasting blood glucose and Digit Symbol Coding (P=.0360), and HbA1C and DSC (P=.0477).

However, investigators noted weight loss appeared to have mixed associations with cognitive scoresnoting greater BMI reduction and worse auditory verbal learning test scores overall (P=.0053) while greater BMI reduction and better digit symbol coding scores were observed among patients who were overweight but not obese (P=.010).

Results of the study also indicated apparent associations were strongest among patients who were overweight but not obese at baseline. Additionally, investigators pointed out associations appeared to also be stronger Amon those with a history of cardiovascular disease at baseline.

"The results were worse for people who had obesity at the beginning of the study. That's a 'too little, too late' type of message," added Carmichael, in the aforementioned statement. "People with diabetes who let their obesity go too far, for too long may be past the point of no return, cognition-wise."

This study, Long-term change in physiological markers and cognitive performance in type 2 diabetes: the Look AHEAD Study, was published in the Journal of Clinical Endocrinology and Metabolism.

Original post:
Blood Sugar Control Could Help Protect Neurologic Health in Patients with Diabetes - Endocrinology Network

The Center for Regenerative Medicine in Miami, Florida, helps patients get back to a functional level of life and activities using Regenerative medicine and autologous therapy. Since 2000, the Center has developed non-surgical and rehabilitation techniques to treat and manage various diseases related to Neurology, Ophthalmology, and Orthopedics.

The Center for Regenerative Medicine includes a team of dedicated professionals working with cutting edge medical technology. The Center has patients from around the world including celebrities, sports legends, professional athletes, amateur athletes, dancers, and more.

The Center for Regenerative Medicines core values are as follows:

The Founder/Director of the Center for Regenerative Medicine is Alimorad Farshchian, MD. He is a medical doctor, medical author, and humanitarian. In 2005, Dr. Farshchian was the first doctor in the U.S.A. to perform an autologous biologics transplantation into an arthritic knee. Dr. Farshchian served as the TEAM USA Track & Field Orthopedic Regenerative Medicine consulting physician, for the 2012 London Olympics and the 2016 Rio Olympics.

For more information and patient testimonials, visit http://www.NeuroRegenesis.com

The Center for Regenerative Medicine in Miami, Florida concentrates on helping patients to get back to a functional level of life and their activities using Regenerative medicine.

Founded in 2000 by Dr. A.J. Farshchian, medical director of the center in order to pursue pioneering regimens in the treatment of arthritis and neurodegenerative diseases. The Center for Regenerative Medicine has over 20 years experience in Neurological diseases and more than 50,000 cases treated.

Above content provided by The Center for Regenerative Medicine.

See more here:
The Center For Regenerative Medicine Has Over 20 Years Experience In Neurological Diseases, More Than 50,000 Cases Treated - CBS Miami

CRANBURY, N.J., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, today announced the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to AT-GTX-501, the Companys investigational gene therapy for children living with variant late infantile neuronal ceroid lipofuscinosis 6 (vLINCL6) disease, also known as CLN6 Batten disease.

The PRIME initiative provides enhanced support and increased interaction to developers of promising medicines with the goal of optimizing development plans and speeding regulatory evaluations. The goal of EMAs PRIME is to help patients benefit as early as possible from innovative new therapies that have demonstrated the potential to significantly address an unmet medical need.

The PRIME designation is based on data from the ongoing Phase 1/2 clinical trial evaluating a single dose of AT-GTX-501 for the treatment of children with CLN6 Batten disease. Additional information about the trial is available at ClinicalTrials.gov (NCT02725580).

We are very pleased that the EMA has recognized the potential of our CLN6 gene therapy. Based on our preliminary clinical data, we believe AT-GTX-501 could potentially be a transformative treatment option for children living with CLN6 Batten disease, an ultra-rare, debilitating condition that presents in early childhood and is often associated with childhood death, said John F. Crowley, Chairman and Chief Executive Officer. We look forward to continuing to work closely with the EMA to accelerate development of this first potential treatment option for children living with CLN6 Batten disease.

Additional data from the ongoing Phase 1/2 clinical study will be presented at the Child Neurology Society Annual Meeting in October. Regulatory interactions are ongoing and the Company expects to provide feedback on the path forward in early 2021.

In the U.S., AT-GTX-501 previously was granted Rare Pediatric Disease and Orphan Drug designations by the United States Food and Drug Administration. In the EU, the Company now holds PRIME and orphan medicinal product designations.

About AT-GTX-501AT-GTX-501 is a novel gene therapy in Phase 1/2 development for CLN6 Batten disease, a rare, fatal, inherited lysosomal disorder with no approved treatment that primarily affects the nervous system. AT-GTX-501 is dosed in a one-time intrathecal infusion to deliver a functional copy of the CLN6 gene to cells of the central nervous system. The therapy is designed to address the underlying enzyme deficiency that results in progressive cell damage and neurodevelopmental and physical decline.

About Batten DiseaseBatten disease is the common name for a broad class of rare, fatal, inherited disorders of the nervous system also known as neuronal ceroid lipofuscinoses, or NCLs. In these disorders, a defect in a specific gene triggers a cascade of problems that interferes with a cells ability to recycle certain molecules. Each gene is called CLN (ceroid lipofuscinosis, neuronal) and given a different number designation as its subtype. There are 13 known forms of Batten disease often referred to as CLN1-8; 10-14. The various types of Batten disease have similar features and symptoms but vary in severity and age of onset.

Most forms of Batten disease/NCLs usually begin during childhood. The clinical course often involves progressive loss of independent adaptive skills such as mobility, feeding and communication. Patients may also experience vision loss, personality changes, behavioral problems, learning impairment and seizures. Patients typically experience progressive loss of motor function and eventually become wheelchair-bound, are then bedridden and die prematurely.

About Amicus TherapeuticsAmicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases. For more information please visit the companys website at http://www.amicusrx.com, and follow on Twitter and LinkedIn.

Forward-Looking StatementsThis press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of our product candidates, the timing and reporting of results from preclinical studies and clinical trials and the prospects and timing of the potential regulatory approval of our product candidates. In particular, this press release relates to interim data from an ongoing Phase 1/2 study to investigate intrathecal administration of AAV-CLN6 gene therapy. The inclusion of forward-looking statements arising from this interim data, ongoing study and natural history preliminary data should not be regarded as a representation by us that any of our plans will be achieved. Any or all of the forward-looking statements in this press release may turn out to be wrong and can be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. For example, with respect to statements regarding the goals, progress, timing, and outcomes of discussions with regulatory authorities, and in particular the potential goals, progress, timing, and results of preclinical studies and clinical trials, actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in our business, including, without limitation: the potential that results of clinical or preclinical studies indicate that the product candidates are unsafe or ineffective; the potential that it may be difficult to enroll patients in our clinical trials; the potential that regulatory authorities, including the FDA, EMA, and PMDA, may not grant or may delay approval for our product candidates; the potential that preclinical and clinical studies could be delayed because we identify serious side effects or other safety issues; and the potential that we will need additional funding to complete all of our studies. Further, the results of earlier preclinical studies and/or clinical trials may not be predictive of future results. The interim data and Phase 1/2 study discussed herein is inherently preliminary and early in the study, derived from a limited patient set, and later trial results with this patient set or others may not be consistent with these preliminary results. In addition, all forward-looking statements are subject to other risks detailed in our Annual Report on Form 10-K for the year ended December 31, 2019 and Quarterly Report on Form 10-Q for the quarter ended June 30, 2020. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and we undertake no obligation to revise or update this news release to reflect events or circumstances after the date hereof.

CONTACTS:

Investors:Amicus TherapeuticsAndrew FaughnanDirector, Investor Relationsafaughnan@amicusrx.com(609) 662-3809

Media:Amicus TherapeuticsDiana MooreHead of Global Corporate Communicationsdmoore@amicusrx.com(609) 662-5079

FOLDG

Originally posted here:
Amicus Therapeutics Receives European Medicines Agency PRIME Designation for CLN6 Batten Disease Gene TherapyAdditional Phase 1/2 Data to be Presented...

This article was originally published here

Neurol Sci. 2020 Sep 24. doi: 10.1007/s10072-020-04723-9. Online ahead of print.

ABSTRACT

The worldwide SARS-CoV-2 pandemic is dramatically affecting health systems with consequences also for neurological residency training. Here we report early experiences and challenges that European neurologists and residents faced. The breadth of the pandemic and the social restrictions induced substantial modifications in both inpatient and outpatient clinical care and academic activities as well, adversely affecting our residency training. On the other hand we see also opportunities, such as gaining more clinical and professional skills. All these drastic and sudden changes lead us to reconsider some educational aspects of our training program that need to be improved in order to better prepare the neurologists of the future to manage unexpected and large emergency situations like the one we are living in these days. A reconsideration of the neurological training program could be beneficial to guarantee high standard level of the residency training in this period and beyond.

PMID:32970238 | DOI:10.1007/s10072-020-04723-9

Read more:
COVID-19 and neurological training in Europe: from early challenges to future perspectives - DocWire News

- Corporate restructuring to extend cash runway through mid-2022 and key milestones -

- UBX1325 to enter clinical development in patients with diabetic macular edema -

SAN FRANCISCO, Calif., Sept. 15, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced it has initiated a restructuring to align its resources on cellular senescence programs in ophthalmology and neurology while further extending operating capital. UNITY will advance UBX1325 to Phase 1 clinical development in patients with diabetic macular edema, and expects to dose the first patient in the second half of 2020, consistent with prior guidance.

UNITY has prioritized its portfolio and aligned resources to deliver on key development milestones and drive innovation:

Revised Financial Guidance

UNITY will reduce its workforce by approximately 30% to optimize capital allocation and align with key strategic priorities, resulting in an estimated 75 full-time employees by the end of the year. These steps to focus resources are expected to extend the cash runway through mid-2022, with current cash and cash equivalents projected to fund UNITY through key clinical data readouts for UBX1325 and IND-enabling studies for UBX1967.

"UNITY is a pioneer in the development of therapeutics targeting senescent cells at the crux of many age-related diseases, and we will continue to build on this scientific foundation as we advance our pipeline," said Anirvan Ghosh, Ph.D., chief executive officer of UNITY. "At UNITY, we have an extraordinary team that has contributed greatly to the advancement of this field, and we are deeply grateful for the contributions that all of our employees have made. Moving forward we will have a leaner and more agile team, which is well-resourced to advance our pipeline programs to key milestones."

Dr. Ghosh added: We are excited about advancing UNITYs lead ophthalmology program, UBX1325, into clinical studies in patients with diabetic macular edema, an indication with a well-defined development path and objective endpoints. In addition, I see significant opportunities emerging from programs in our preclinical pipeline targeting ophthalmologic and neurologic disease. I look forward to using my experience leading drug discovery and development programs in these areas to advance the development of a new class of high efficacy therapies.

About UNITYUNITY is developing a new class of therapeutics to slow, halt or reverse diseases of aging. UNITY's current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. More information is available atwww.unitybiotechnology.comor follow us onTwitter.

Forward-Looking Statements

This press release contains forward-looking statements including statements related to UNITYs understanding of cellular senescence and the role it plays in diseases of aging, the potential for UNITY to develop therapeutics to extend healthspan, including for ophthalmologic and neurologic disease, the potential for UNITY to successfully commence and complete clinical studies of UBX1325 for diabetic macular edema and other ophthalmological diseases, the expected timing of initial results of the Phase 1 study of UBX1325 in diabetic macular edema, the expected size of UNITYs workforce following the restructuring, the impact of the workforce reduction on UNITYs business, and UNITYs expectations regarding the sufficiency of its cash runway. These statements involve substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements, including the risk that the COVID-19 worldwide pandemic may continue to negatively impact the development of preclinical and clinical drug candidates, including delaying or disrupting the enrollment of patients in clinical trials. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. The forward-looking statements in this press release represent our views as of the date of this release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this release. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see UNITYs most recent Quarterly Report on Form 10-Q for the quarter ended June 30, 2020, filed with the Securities and Exchange Commission on July 31, 2020, as well as other documents that may be filed by UNITY from time to time with the Securities and Exchange Commission.

Continue reading here:
UNITY Biotechnology Announces Actions to Focus on Senolytic Programs in Ophthalmology and Neurology - Yahoo Finance

This study of ischemic stroke patients is the first to associate the neutrophil-lymphocyte ratio in patients with COVID-19 and ischemic stroke and stroke severity.

Chen Lin, M.D.,assistant professor in the UAB Department of NeurologyStroke patients who also have COVID-19 showed increased systemic inflammation, a more serious stroke severity and a much higher rate of death, compared to stroke patients who did not have COVID-19, according to University of Alabama at Birmingham research led by Chen Lin, M.D., an assistant professor in the UAB Department of Neurology.

The research, published in the journal Brain, Behavior & Immunity Health, is a retrospective, observational, cross-sectional study of 60 ischemic stroke patients admitted to UAB Hospital between late March and early May 2020. Ischemic stroke occurs when a blood vessel for the brain is blocked by a clot, depriving some brain tissue of oxygen. All patients were tested for COVID-19 at admission.

The UAB researchers mined electronic medical records of confirmed stroke cases for information on age, gender and race; clinical variables; laboratory data, including complete blood counts, blood chemistry and coagulation tests; and outcomes, including death, length of hospital stay and condition at discharge.

The ratio of the number of neutrophils to the number of lymphocytes, or the NLR, as calculated from blood count data, served as an index of the systemic inflammatory response. While other researchers have associated NLR with COVID-19 disease severity, refractory disease and even as an independent factor for mortality, our study is the first to associate the NLR in patients with COVID-19 and ischemic stroke and stroke severity, Lin said.

Of the 60 hospitalized patients with acute systemic stroke, nine were positive for a COVID-19 infection.

The UAB research had four major findings. First, patients who were positive for COVID-19 presented with a more severe neurological deficit at admission, as measured by the National Institutes of Health Stroke Scale, or NIHSS, score, which averaged 18.4. Second, all patients with an NIHSS score higher than 4 including uninfected patients had a significantly higher NLR than those with lower scores. The NIHSS is used to predict lesion size and gauge stroke severity.

Third, patients with COVID-19 had an increased inflammatory response, including significantly higher neutrophil counts, lower lymphocyte counts and an increased NLR, compared with uninfected patients. Finally, stroke patients with COVID-19 had a significantly higher mortality rate 44.4 percent, versus 7.6 percent for uninfected stroke patients.

Two other studies this year have reported clinical and laboratory differences in ischemic stroke patients with and without COVID-19, Lin says, but neither addressed racial differences or NLR differences between groups.

Diana M. Lin, UAB Department of PathologyWe have reported the first experience within the Stroke Belt of the Southern United States, which has the highest proportion of African American stroke patients, said Lin, who is also the director of the Stroke Recovery Clinic in the UAB Division of Cerebrovascular Disease. In the UAB study, African Americans comprised 55.6 percent of those who had COVID-19 and stroke and 37.7 percent of those with only stroke.

Interestingly, in our patients with stroke and COVID-19, the neutrophil and lymphocyte levels were only borderline high and low, respectively, Lin said, yet the NLR was almost twice as high as in patients without COVID-19. This potentially indicates that the systemic inflammatory response triggered by COVID-19 can cascade from multiple components.

Co-authors with Lin for the study, Racial differences and an increased systemic inflammatory response are seen in patients with COVID-19 and ischemic stroke, are Yurany A. Arevalo, UAB Department of Neurology; Hely D. Nanavati, Department of Epidemiology, UAB School of Public Health; and Diana M. Lin, UAB Department of Pathology.

See the rest here:
Stroke patients with COVID-19 have increased inflammation, stroke severity and death - The Mix

Pediatric Neurology Device Market Scenario 2020-2026:

The Global Pediatric Neurology Device market exhibits comprehensive information that is a valuable source of insightful data for business strategists during the decade 2014-2026. On the basis of historical data, Pediatric Neurology Device market report provides key segments and their sub-segments, revenue and demand & supply data. Considering technological breakthroughs of the market Pediatric Neurology Device industry is likely to appear as a commendable platform for emerging Pediatric Neurology Device market investors.

This Pediatric Neurology Device Market Report covers the manufacturers data, including shipment, price, revenue, gross profit, interview record, business distribution, etc., these data help the consumer know about the competitors better.

Get Sample Report: https://grandviewreport.com/sample/54739

The complete value chain and downstream and upstream essentials are scrutinized in this report. Essential trends like globalization, growth progress boost fragmentation regulation & ecological concerns. This Market report covers technical data, manufacturing plants analysis, and raw material sources analysis of Pediatric Neurology Device Industry as well as explains which product has the highest penetration, their profit margins, and R&D status. The report makes future projections based on the analysis of the subdivision of the market which includes the global market size by product category, end-user application, and various regions.

Topmost Leading Manufacturer Covered in this report:Elana, Inova Healthcare System, Medtronic, The Nemours Foundation, Stryker, Boston Scientific, B.Braun Melsungen, Integra LifeSciences, St. Jude Medical

Product Segment Analysis: Neurosurgery Devices, Neurostimulator, Cerebrospinal Fluid (CSF) Management Devices

Application Segment Analysis:

HospitalsHealthcare CentersNeurological Research Centers

Get Discount @ https://grandviewreport.com/discount/54739

Regional Analysis For Pediatric Neurology DeviceMarket

North America(the United States, Canada, and Mexico)Europe(Germany, France, UK, Russia, and Italy)Asia-Pacific(China, Japan, Korea, India, and Southeast Asia)South America(Brazil, Argentina, Colombia, etc.)The Middle East and Africa(Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

Market Synopsis:The market research report consists of extensive primary research, as well as an in-depth analysis of the qualitative and quantitative aspects by various industry specialists and professionals, to gain a deeper insight into the market and the overall landscape.

The objectives of the report are:

To analyze and forecast the market size of Pediatric Neurology DeviceIndustry in theglobal market. To study the global key players, SWOT analysis, value and global market share for leading players. To determine, explain and forecast the market by type, end use, and region. To analyze the market potential and advantage, opportunity and challenge, restraints and risks of global key regions. To find out significant trends and factors driving or restraining the market growth. To analyze the opportunities in the market for stakeholders by identifying the high growth segments. To critically analyze each submarket in terms of individual growth trend and their contribution to the market. To understand competitive developments such as agreements, expansions, new product launches, and possessions in the market. To strategically outline the key players and comprehensively analyze their growth strategies.

View Full Report @ https://grandviewreport.com/industry-growth/Pediatric-Neurology-Device-Market-54739

At last, the study gives out details about the major challenges that are going to impact market growth. They also report provides comprehensive details about the business opportunities to key stakeholders to grow their business and raise revenues in the precise verticals. The report will aid the companys existing or intend to join in this market to analyze the various aspects of this domain before investing or expanding their business in the Pediatric Neurology Device markets.

Contact Us:Grand View Report(UK) +44-208-133-9198(APAC) +91-73789-80300Email : [emailprotected]

View post:
Pediatric Neurology Device Market Detailed analysis of current Industry figures with forecasts growth by 2026 | Elana, Inova Healthcare System,...

Most seizure medications carry a life-and-death warning: Taking this drug may increase suicide risk. Now researchers, includingMichael Sperling, MD, a professor in the department of Neurology and Director of the Clinical Neurophysiology Laboratory and the Comprehensive Epilepsy Center at Thomas Jefferson University, have discovered that the warning does not apply to many antiseizure drugs.

A new analysis, initiated by Pavel Klein, MD, a neurologist at the Mid-Atlantic Epilepsy and Sleep Center in Bethesda revealed no evidence for increased suicide risk from recently developed antiseizure medications. Despite the lack of data, all anti-seizure medications carry the warning from the U.S. Food and Drug Administration (FDA). The findings, reported today (August 2, 2021) in JAMA Neurology,call on the FDA to change its approach for applying class warnings to medication.

The approach the FDA has taken is concerning for doctors and patients alike because its not evidence based, says Dr. Sperling.

In 2008, the FDA analyzed results from nearly 200 clinical trials that assessed the efficacy of many drugs including 11 anti-seizure medications. The analysis revealed that compared with placebo, anti-seizure medications nearly doubled suicide risk among patients being treated for epilepsy, psychiatric disorders, and other diseases including chronic pain. The FDA concluded that anti-seizure medications increase suicide risk.

However, subsequent analyses did not find the same results. Yet, as a result of the FDA study, all anti-seizure medications approved since 2008 carry a warning for suicidality.

The warning affected the way new drugs are developed, which then impacted patient treatment. Trials of anti-seizure drugs since the warning came out have been careful to assess suicidality, but have also excluded people with histories of suicidal ideation. This means that trial results are difficult to extrapolate to patient treatment.

Now when a patient with epilepsy and a history of suicidal ideation comes into my office, I know nothing about whether any drug that I could prescribe is particularly risky to that individual or not, Dr. Sperling said.

Another concern is that patients may be reluctant to start or keep taking anti-seizure medications because of the warning. For patients with epilepsy, however, not taking their medications could mean more seizures, and a risk of dying from increased seizures.

Drs. Klein and Sperling wanted to find out if the warning actually applied to drugs approved since the FDAs study in 2008.

The researchers reviewed all randomized, placebo-controlled phase II and III clinical trials of the five new antiseizures medicationseslicarbazepine, perampanel, brivaracetam, cannabidiol (epidiolex) and cenobamateapproved by the FDA since 2008 that assessed suicidality. In total, they evaluated the results of 17 studies involving nearly 6000 patients.

They found no evidence for increased risk of suicidal thinking or behavior in the five drugs. Suicidal thinking or behavior occurred in 12 of the 4000 actively-treated patients in the trial (0.3%) and seven out of nearly 2000 placebo-treated patients (0.35%).

Our findings indicate the nonspecific suicide warning for all epilepsy drugs is simply not justifiable, says Dr. Sperling. The results are not surprising. Different drugs affect cells in different ways. So theres no reason to expect that every drug would increase suicide risk for every patient.

Although he acknowledges that some patients with epilepsy have pre-existing depression and perhaps are at greater risk for suicidal ideation, most do not.

Theres no reason to think that somebody with no history of depression and no risk for it would necessarily be at an increased risk for suicidality, he adds.

As some of the same brain chemistry that underlies epilepsy may be at play in depression, Dr. Sperling advises patients to pay attention to how they are feeling and to let their doctors know if they are having suicidal thoughts.

Patients and doctors must balance risks. The risk of epilepsy and seizures that are not controlled is greater than the risk of suicidality from anti-seizure medications that the FDA has highlighted, he says.

Dr. Sperling hopes that the evidence speaks for itself and that the FDA will reconsider their blanket-warnings on classes of drugs. Without the evidence to support it, the net effect of such class risk on drugs have consequences that may be worse if patients are afraid to take their medication, he says.

Reference: Suicidality risk of newer anti-seizure medications: a meta-analysis by Klein, P., Devinsky, O., French, J., Harden C., Krauss, G., McCarter, R., and Sperling. M., 2 August 2021, JAMA Neurology.DOI: 10.1001/jamaneurol.2021.2480

See the article here:
Most Seizure Medications Carry a Life-and-Death Warning Heres the Problem - SciTechDaily

New York, Sept. 18, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Surgical Table Market Research Report by Technology, by Surgery Type, by Material, by End-use - Global Forecast to 2025 - Cumulative Impact of COVID-19" - https://www.reportlinker.com/p05968803/?utm_source=GNW

The Global Surgical Table Market is expected to grow from USD 921.67 Million in 2019 to USD 1,592.67 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 9.54%.

Market Segmentation & Coverage:This research report categorizes the Surgical Table to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Technology, the Surgical Table Market studied across Electric, Hydraulic, and Manual.

Based on Surgery Type, the Surgical Table Market studied across Bariatric Surgical Table, General Surgical Table, Neurology Surgical Table, Orthopaedic Surgical Table, Specialty Surgical Table, and Urology Surgical Table.

Based on Material, the Surgical Table Market studied across Composite and Metal.

Based on End-use, the Surgical Table Market studied across Ambulatory Surgical Centers and Hospitals.

Based on Geography, the Surgical Table Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Company Usability Profiles:The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Surgical Table Market including AGA Sanittsartikel GmbH, ALVO Limited Liability Company Sp. k., Amtai Medical Equipment Inc, Berchtold GmbH & Co. KG, BRUMABA GmbH & Co. KG, Denyers International PTY, Eschmann Holdings Ltd, Getinge AB, Heal Force Bio-meditech Holdings Limited, Hill-Rom Holdings Inc, Infinium Medical, Lojer Oy, Merivaara Corp., Mizuho Medical Co. Ltd, Narang Medical Limited, S I Surgical Private Limited, Skytron LLC, Staan Bio-Med Engineering Private Limited, Steris PLC, and Stille AB.

FPNV Positioning Matrix:The FPNV Positioning Matrix evaluates and categorizes the vendors in the Surgical Table Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Competitive Strategic Window:The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.

Cumulative Impact of COVID-19:COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.

The report provides insights on the following pointers:1. Market Penetration: Provides comprehensive information on the market offered by the key players2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments

The report answers questions such as:1. What is the market size and forecast of the Global Surgical Table Market?2. What are the inhibiting factors and impact of COVID-19 shaping the Global Surgical Table Market during the forecast period?3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Surgical Table Market?4. What is the competitive strategic window for opportunities in the Global Surgical Table Market?5. What are the technology trends and regulatory frameworks in the Global Surgical Table Market?6. What are the modes and strategic moves considered suitable for entering the Global Surgical Table Market?Read the full report: https://www.reportlinker.com/p05968803/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Original post:
Surgical Table Market Research Report by Technology, by Surgery Type, by Material, by End-use - Global Forecast to 2025 - Cumulative Impact of...

TORONTO, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Newscope Capital Corporation (CSE: PHRM) (OTCQB: PHRRF), who through its wholly-owned subsidiary, PharmaTher Inc. (PharmaTher), is a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals, is pleased to announce that PharmaTher has entered into an Exclusive Worldwide License Agreement (the Agreement) with the National Health Research Institutes (NHRI) for the development and commercialization of a patented combination formulation of FDA-approved ketamine and betaine (KETABET) as a potential next-generation ketamine treatment for mental health, neurological and pain disorders.

KETABET has shown in clinical research to enhance the antidepressant effect while having the potential to significantly reduce the known negative side effects of ketamine.1 Side effects such as hallucinations, confusion, memory loss and abuse liability compromise the compliance and potential therapeutic value of ketamine.

Through a proprietary microneedle (MN) patch, KETABET aims to empower patients to dose their medication remotely, safely and conveniently rather than being under supervision by a healthcare provider at a certified medical office. KETABET MN patch has the potential to incorporate anti-tampering and anti-abuse features because of the combined presence of ketamine and betaine and the delivery format of the product that would parallel the approach used for the tamper-resistant transdermal fentanyl patch.

PharmaTher will seek FDA approval to conduct a Phase II clinical study for KETABET targeting the more than 300 million people who suffer from major depressive disorder and 100 million people who are resistant to available treatments worldwide.

We believe KETABET has the potential to change the way mental health, neurological and pain disorders will be treated for the hundreds of millions of people globally who are suffering from these debilitating conditions, said Fabio Chianelli, CEO of PharmaTher. We are pursuing the clinical development of KETABET to overcome the current limitations of ketamine and to unlock the known potential therapeutic value of ketamine for FDA approval.

Currently, pharmaceutical companies are developing new types of antidepressants. Approved antidepressants have significant limitations, including delayed response rates and unwanted side effects causing poor patient compliance and low remission rates.

Ketamine was approved by the FDA in 1970 and is clinically used for analgesia, sedation, and anesthetic induction.

Ketamine is emerging as a viable treatment option for depression. Recent clinical studies have shown that low dose ketamine produces a rapid-acting and sustained antidepressant effect in major depressive disorder2, bipolar depression3, depression with suicidal ideation4 and post-traumatic stress disorder5. Despite this, the potential for abuse and misuse of ketamine and the adverse mental effects of ketamine use such as dissociative, hallucinogenic, and amnesic effects6 leads to its limited clinical use and discontinuation.

The FDA granted Fast Track and Breakthrough Therapy designations for SPRAVATO (esketamine) nasal spray. In March 2019, the FDA approved SPRAVATO, in conjunction with an oral antidepressant, for treatment-resistant depression to Janssen Pharmaceuticals, Inc. According to the FDA, because of the risk of serious adverse outcomes resulting from sedation and dissociation caused by Spravato administration, and the potential for abuse and misuse of the drug, it is only available through a restricted distribution system, under a Risk Evaluation and Mitigation Strategy.7 The estimated annual cost per patient for SPRAVATO could cost up to $49 thousand with limited reimbursement, whereas intravenous ketamine could cost up to $5,000 per patient annually without any reimbursement. Both require numerous administration sessions in a certified medical office under medical supervision by a health care provider.

COMPASS Pathways plc is developing COMP360 psilocybin therapy to be administered in conjunction with psychological support for treatment-resistant depression. In 2019, Compass Pathways plc completed a Phase I clinical trial and is currently evaluating COMP360 in a Phase IIb trial. The therapy protocol for COMP360, which would last approximately six to eight hours, includes the presence of a therapist and assisting therapist throughout the treatment session.8

PharmaTher aims to develop KETABET in a proprietary microneedle patch for FDA approval in certain mental health, neurological and pain disorders and provide the patient with a potentially convenient, safe and effective ketamine treatment through the combination of two FDA-approved drugs, ketamine and betaine.

Betaine anhydrous (CYSTADANE) was approved by the FDA in 1996 for the treatment of homocystinuria to decrease elevated homocysteine blood concentrations.

There is growing evidence that betaine plays a critical role in regulating brain functions and has an antidepressant-like effect.9 Betaine has been reported to prevent seizures in rodents10, to improve symptoms of Rett syndrome11, and to delay the onset of neurologic impairment due to vitamin B12 deficiency12 clinically. Furthermore, betaine attenuates memory deficits induced by homocysteine.13

Based on preclinical studies that supported the granted patent and patent applications of KETABET, the combination of ketamine and betaine produced more robust antidepressant-like responses than their individual effects and that the combination blocked the psychotomimetic effects of ketamine.1 This suggests that betaine can be considered as an add-on therapy to ketamine or as a fixed-dose combination therapy for treatment-resistant depression, treatment-resistant bipolar disorder, post-traumatic stress disorder, obsessive-compulsive disorder and chronic pain.

Under the terms of the Agreement, PharmaTher gained exclusive worldwide development and commercial rights to an intellectual property portfolio consisting of a granted patent (Taiwan patent: I648049) and patent applications (International Publication Number: WO2017205666A1) titled, Method and composition for decreasing the psychotomimetic side effect and addictive disorder of ketamine in the U.S., Europe, Japan, Canada, Israel and China.

Consistent with industry standards, PharmaTher paid a one-time fee for entering into the Agreement, and all other future payments will be based on clinical trial and revenue milestones reached by PharmaTher.

About The National Health Research Institutes

The National Health Research Institutes (NHRI) is a non-profit foundation established in 1995 by the government of Taiwan. Being an autonomous research organization under the supervision of the Department of Health, the NHRI is dedicated to the enhancement of medical research and the improvement of health care in this country. Scientists at the NHRI conduct mission-oriented medical research and investigate many aspects of the basic biomedical sciences, as well as specific diseases. These range from the common problems such as aging, cancer, infectious diseases, mental disorders, occupational diseases, to health policy. For more information about the NHRI visit http://www.nhri.edu.tw.

About PharmaTher Inc.

PharmaTher Inc., a wholly-owned subsidiary of Newscope Capital Corporation (CSE: PHRM) (OTCQB: PHRRF), is a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals, such as ketamine and psilocybin, for FDA approval to treat mental health, neurological and pain disorders.

Learn more at:PharmaTher.comand follow us on Twitter,LinkedIn andFacebook.

For more information, please contact:

Fabio ChianelliChief Executive OfficerPharmaTher Inc.Tel: 1-888-846-3171Email: info@pharmather.comWebsite: http://www.pharmather.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.

Cautionary Statement

This press release contains forward-looking information within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words could, intend, expect, believe, will, projected, estimated, potential and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on theNewscope Capital Corporations (the Company)current belief or assumptions as to the outcome and timing of such future events. Forward-looking information in this press release includes information with respect to development and commercialization of a patented combination formulation of FDA-approved ketamine and betaine (KETABET) as a potential next-generation ketamine treatment for mental health, neurological and pain disorders, KETABET aims to empower patients to dose their medication remotely, safely and conveniently rather than being under supervision by a healthcare provider at a certified medical office, KETABET MN patch has the potential to incorporate anti-tampering and anti-abuse features, seek FDA approval to conduct a Phase II clinical study, intellectual property portfolio,psychedelic pharmaceuticals,psilocybin andketamine programs and product developments.Forward-looking information is based on reasonable assumptions that have been made by the Company at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. Given these risks, uncertainties and assumptions, you should not unduly rely on these forward-looking statements. The forward-looking information contained in this press release is made as of the date hereof, and Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The foregoing statements expressly qualify any forward-looking information contained herein. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under the caption Risk Factors in Companys managements discussion and analysis for the period of August 30, 2020 (MD&A), dated October 1, 2020, which is available on the Companys profile atwww.sedar.com.

This news release does not constitute an offer to sell or the solicitation of an offer to buy, and shall not constitute an offer, solicitation or sale in any state, province, territory or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state, province, territory or jurisdiction.

References:

More:
PharmaTher Signs Exclusive Worldwide License Agreement for Patented Ketamine Formulation Targeting Mental Health, Neurological and Pain Disorders -...

Although many people get coronavirus and may not even know it, others can experience mild symptomsand then get worse. Potentially for life. They are called Long Haulers and they have Long COVID. "Three quarters of patients hospitalized with COVID-19 had at least one ongoing symptom 6 months after their acute illness," say the authors of a new presentation on the CDC website, written by clinicians on the front lines. And furthermore, many who weren't hospitalized can remain ill too. Keep reading to discover the most common symptoms of what's being called Long COVIDand to ensure your health and the health of others, don't miss these Sure Signs You've Already Had Coronavirus.

"Persons with long COVID often present reporting persistent severe fatigue," says Alfonso C Hernandez-Romieu, MD, MPH, LCDR, U.S. Public Health Service, Late Sequelae Unit, Clinical Team, COVID-19 Response, Centers for Disease Control and Prevention, in the presentation. "The most comprehensive longitudinal data is from a recently published Chinese cohort. Among 1,733 patients, 3/4 of patients hospitalized with COVID-19 have at least one ongoing symptom six months after their acute illness, with 63% endorsing fatigue and muscle weakness."

Brain fog is "defined as mild subjective cognitive impairment," says Dr. Hernandez-Romieu. Dr. Anthony Fauci, the chief medical advisor to the President and the director of the National Institute of Allergy and Infectious Diseases, has called this an "inability to concentrate." You might also feel memory loss, confusion and a "foggy" feeling.

These can feel like a jackhammer and not stop. And unfortunately: "There aren't any specific treatments we have for post-COVID neurologic symptoms," Dr. Felicia Chow, MD, associate professor of neurology and medicine at the University of California, San Francisco, tells Neurology Today. "It's symptomatic management of the issues they're having, whether that's headache or dizziness or cognitive complaints."

26% of those in the study had difficulty sleeping. Insomnia, vivid dreams (or nightmares) and nighttime hallucinations have all been reported by long haulers. "The virus is capable of altering the delicate processes within our nervous system, in many cases in unpredictable ways, sometimes creating long-term symptoms," says the Atlantic. "Better appreciating the ties between immunity and the nervous system could be central to understanding COVID-19and to preventing it."

26% of those in the study had dyspnea. "Few sensations are as frightening as not being able to get enough air," reports the Mayo Clinic. "Shortness of breath known medically as dyspnea is often described as an intense tightening in the chest, air hunger, difficulty breathing, breathlessness or a feeling of suffocation."

23% in the study suffered anxiety or depression. "A lot of these patients have depression, anxiety or PTSD from their experience with COVID," said Dr. Allison P. Navis, MD, assistant professor in the division of neuro-infectious diseases at the Icahn School of Medicine at Mount Sinai in Neurology Today. "I try to address the mental health aspects, to let patients know it's okay if they're dealing with that." Dr. Ross Zafonte, DO, chair of the Harvard Medical School department of physical medicine and rehabilitation at Spaulding, told the journal: "Some of these patients can have an affective issue that could be making things worse. Depression or PTSD can have a real impact on their other symptoms. What I've noticed is that these post-COVID symptoms are really, really multi-factorial."

Actress Alyssa Milano is perhaps the most notable long hauler who lost her hair after contracting COVID. "Thought I'd show you what #Covid19 does to your hair," Milano captioned a video, of her hair loss. "Please take this seriously. #WearADamnMask #LongHauler."

As you likely know, COVID can cause one to lose their sense of taste or smell. For some patients, these senses never come back. According to Advisory Board: "Narly 25% of Covid-19 patients who reported losing their sense of smell said they did not regain their olfactory function even 60 days after they noticed it was gone, according to a large prospective study in the Journal of Internal Medicinea potentially pervasive loss that providers believe could affect patients' nutrition and mental health."

"As Chimre Smith clicked on the link to join the COVID-19 Slack support group, she could feel her body shaking. Not because of an internal buzzing sensation reported by some people struggling with the illness though she is certainly familiar with that," reported the Washington Post. "Smith, a 38-year-old Baltimore middle school teacher, fell ill in March with symptoms progressing rapidly from a sore throat to crushing fatigue to heart palpitations. Still dealing with symptoms several weeks in, she was confused and afraid but alive though that, it seemed, could change at any moment."

RELATED: Simple Ways to Avoid a Heart Attack, According to Doctors

"Many of the symptoms of the coronavirus mimic the typical symptoms of a viral infection or flu syndrome," says Dr. Stuart J. Fischer in OrthoInfo. "One of these symptoms may be muscle aches or myalgias. You may get pain in your arms, legs, or back that develops spontaneously with no injury. Typically, in a coronavirus infection, the pain is in muscles rather than in joints. But if you have an arthritic joint in your arm or leg, the virus may exaggerate the symptoms. The pain may be severe and limiting."

"Another important finding among patients attending the post-acute COVID clinic in France was that more than 1/4 developed new neurological signs and symptoms after their acute COVID-19 illness," says Dr. Hernandez-Romieu. "These included but were not limited to cognitive dysfunction, balanced disorders, paresthesia, and swallowing and speech disorders."

"SARS-CoV-2 infection can also lead to specific complications like stroke, Guillain-Barre Syndrome, and multisystem Inflammatory disorder which can cause prolonged symptoms and disability," says Dr. Hernandez-Romieu.

RELATED: 7 Tips You Must Follow to Avoid COVID, Say Doctors

"Prolonged symptoms are common in patients with mild COVID-19 disease not requiring hospitalization," says Dr. Hernandez-Romieu. "In three studies that focused on people who were not hospitalized for COVID-19 in a post-acute COVID clinic in France, and telephone surveys of patients in the Faroe Islands in Switzerland, anywhere from 35% to 54% of patients had persistent symptoms after two to four months. Half to 3/4 of patients attending the post-acute COVID clinic in France endorsed new symptoms not initially present or symptoms that reappeared after initial resolution."

If you experience these symptoms, contact a medical professional immediately. There is no cure for Long COVID but specialists can potentially alleviate your symptoms with existing medications until there is one. Long COVID support groups like Body Politic can also be extremely useful. And to protect your life and the lives of others, don't visit any of these 35 Places You're Most Likely to Catch COVID.

Read the original post:
Sure Signs You've Already Had COVID, Say COVID Experts - Eat This, Not That

News Release

Tuesday, November 24, 2020

NIH preclinical study suggests FDA-approved tetracycline-based antibiotics may slow infection and reduce neurological problems.

In 2015, hundreds of children were born with brain deformities resulting from a global outbreak of Zika virus infections. Recently, National Institutes of Health researchers used a variety of advanced drug screening techniques to test out more than 10,000 compounds in search of a cure. To their surprise, they found that the widely used antibiotic methacycline was effective at preventing brain infections and reducing neurological problems associated with the virus in mice. In addition, they found that drugs originally designed to combat Alzheimers disease and inflammation may also help fight infections.

Around the world, the Zika outbreak produced devastating, long-term neurological problems for many children and their families. Although the infections are down, the threat remains, said Avindra Nath, M.D., senior investigator at the NIHs National Institute of Neurological Disorders and Stroke (NINDS) and a senior author of the study published in PNAS. We hope these promising results are a good first step to preparing the world for combating the next potential outbreak.

The study was a collaboration between scientists on Dr. Naths team and researchers in laboratories led by Anton Simeonov, Ph.D., scientific director at the NIHs National Center for Advancing Translational Sciences (NCATS) and Radhakrishnan Padmanabhan, Ph.D., Professor of Microbiology & Immunology, Georgetown University Medical Center, Washington, D.C.

The Zika virus is primarily spread by the Aedes aegypti mosquito. In 2015 and 2016, at least 60 countries reported infections. Some of these countries also reported a high incidence of infected mothers giving birth to babies born with abnormally small heads resulting from a developmental brain disorder called fetal microcephaly. In some adults, infections were the cause of several neurological disorders including Guillain-Barr syndrome, encephalitis, and myelitis. Although many scientists have tried, they have yet to discover an effective treatment or vaccination against the virus.

In this study, the researchers looked for drugs that prevent the virus from reproducing by blocking the activity of a protein called NS2B-NS3 Zika virus protease. The Zika virus is a protein capsule that carries long strings of RNA-encoded instructions for manufacturing more viral proteins. During an infection, the virus injects the RNA into a cell, resulting in the production of these proteins, which are strung together, side-by-side, like the parts in a plastic model airplane kit. The NS2B-NS3 protease then snaps off each protein, all of which are critical for assembling new viral particles.

Proteases act like scissors. Blocking protease activity is an effective strategy for counteracting many viruses, said Rachel Abrams, Ph.D., an organic chemist in Dr. Naths lab and the study leader. We wanted to look as far and wide as possible for drugs that could prevent the protease from snipping the Zika virus polyprotein into its active pieces.

To find candidates, Dr. Abrams worked with scientists on Dr. Simeonovs and Dr. Padmanabhans teams to create assays, or tests, for assessing the ability of drugs to block NS2B-NS3 Zika virus protease activity in plates containing hundreds of tiny test tubes. Each assay was tailored to a different screening, or sifting, technique. They then used these assays to simultaneously try out thousands of candidates stored in three separate libraries.

One preliminary screen of 2,000 compounds suggested that commonly used, tetracycline-based antibiotic drugs, like methacycline, may be effective at blocking the protease.

Meanwhile, a large-scale screen of more than 10,000 compounds helped identify an investigational anti-inflammatory medicine, called MK-591, and a failed anti-Alzheimers disease drug, called JNJ-404 as potential candidates. A virtual screen of over 130,000 compounds was also used to help spot candidates. For this, the researchers fed the other screening results into a computer and then used artificial intelligence-based programs to learn what makes a compound good at blocking NS2B-NS3 Zika virus protease activity.

These results show that taking advantage of the latest technological advances can help researchers find treatments that can be repurposed to fight other diseases, said Dr. Simeonov.

The Zika virus is known to preferentially infect stem cells in the brain. Scientists suspect this is the reason why infections cause more harm to newborn babies than to adults. Experiments on neural stem cells grown in petri dishes indicated that all three drugs identified in this study may counteract these problems. Treating the cells with methacycline, MK-591, or JNJ-404 reduced Zika virus infections.

Because tetracyclines are U.S. Food and Drug Administration-approved drugs that are known to cross the placenta of pregnant women, the researchers focused on methacycline and found that it may reduce some neurodevelopmental problems caused by the Zika virus. For instance, Zika-infected newborn mice that were treated with methacycline had better balance and could turn over more easily than ones that were given a placebo. Brain examinations suggested this was because the antibiotic reduced infections and neural damage. Nevertheless, the antibiotics did not completely counteract harm caused by the Zika virus. The weight of mice infected with the virus was lower than control mice regardless of whether the mice were treated with methacycline.

These results suggest that tetracycline-based antibiotics may at least be effective at preventing the neurological problems associated with Zika virus infections, said Dr. Abrams. Given that they are widely used, we hope that we can rapidly test their potential in clinical trials.

Article:

Abrams, R.P.M., Yasgar, A. et al., Therapeutic Candidates for the Zika Virus Identified by a High Throughput Screen for Zika Protease Inhibitors. PNAS, November 23, 2020 DOI: 10.1073/pnas.2005463117.

These studies were supported by NIH Intramural Research Programs at NINDS and NCATS (TR000291) and an NIH grant (AI109185).

For more information:

NINDS (https://www.ninds.nih.gov) is the nations leading funder of research on the brain and nervous system.The mission of NINDS is to seek fundamental knowledge about the brain and nervous system and to use that knowledge to reduce the burden of neurological disease.

About the National Center for Advancing Translational Sciences (NCATS): NCATS conducts and supports research on the science and operation of translation the process by which interventions to improve health are developed and implemented to allow more treatments to get to more patients more quickly. For more information about how NCATS helps shorten the journey from scientific observation to clinical intervention, visit ncats.nih.gov.

About the National Institute of Allergy and Infectious Diseases: NIAID conducts and supports research at NIH, throughout the United States, and worldwide to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID website.

About the National Institutes of Health (NIH):NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.

NIHTurning Discovery Into Health

###

Originally posted here:
Commonly used antibiotic shows promise for combating Zika infections - National Institutes of Health